Sartorius Stedim Biotech (GB:0RG8)
LSE:0RG8
Holding GB:0RG8?
Track your performance easily

Sartorius Stedim Biotech (0RG8) Income Statement

3 Followers

Sartorius Stedim Biotech Income Statement

Last quarter (Q4 2022), Sartorius Stedim Biotech's total revenue was €890.00M, an increase of 14.37% from the same quarter last year. In Q4, Sartorius Stedim Biotech's net income was €186.70M. See Sartorius Stedim Biotech’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
€ 3.49B€ 2.78B€ 3.49B€ 2.89B€ 1.91B€ 1.44B
Cost of Revenue
€ 1.66B-€ 1.66B€ 1.33B€ 906.76M€ 692.28M
Gross Profit
€ 1.83B-€ 1.83B€ 1.55B€ 1.00B€ 748.29M
Operating Expense
€ 751.60M-€ 751.70M€ 670.00M€ 499.88M€ 399.64M
Operating Income
€ 1.08B-€ 1.08B€ 883.00M€ 503.45M€ 348.65M
Net Non Operating Interest Income Expense
€ -9.40M-€ -9.40M€ -6.70M€ -12.10M€ -15.96M
Other Income Expense
------
Pretax Income
€ 1.13B-€ 1.13B€ 646.70M€ 460.69M€ 317.42M
Tax Provision
€ 250.60M-€ 250.50M€ 232.40M€ 122.09M€ 81.38M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ 876.10M-€ 876.10M€ 414.40M€ 335.93M€ 234.50M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
€ 2.41B-€ 2.41B€ 2.00B€ 1.41B€ 1.09B
Net Income From Continuing And Discontinued Operation
€ 876.10M-€ 876.10M€ 414.40M€ 335.93M€ 234.50M
Normalized Income
€ 876.10M-€ 799.62M€ 567.28M€ 359.14M€ 245.87M
Interest Expense
€ 18.60M-€ 18.60M€ 10.40M€ 6.82M€ 4.61M
EBIT
€ 1.15B-€ 1.15B€ 657.10M€ 467.51M€ 322.03M
EBITDA
€ 1.33B€ 755.70M€ 1.33B€ 798.70M€ 569.20M€ 395.40M
Currency in EUR

Sartorius Stedim Biotech Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis